Key Words: Alcohol-associated liver disease; Non-alcoholic fatty liver disease; Mesenchymal stem cells; Cell therapy; Inflammation
Core Tip: Mesenchymal stem cells (MSCs) and their derivatives are a promising therapeutic approach for non-alcoholic fatty liver disease and alcohol-associated liver disease. MSCs, which come from diverse sources and are of low immunogenicity, can attenuate disease progression by modulating key molecular pathways, such as glycolipid metabolism, inflammation, oxidative stress, and fibrosis. In addition, derivatives of MSCs are also considered as a therapeutic strategy due to their ability to retain some of the beneficial effects of MSCs while reducing the risks inherent in cell therapy. However, further studies are needed to emphasize their important mechanistic role in liver injury repair. Refining protocols for the clinical application of MSCs under the prerequisite of a well-defined mechanistic understanding may allow utilizing the full benefits of MSCs in the treatment of liver disease to enhance liver reparability and provide new hope for the treatment of non-alcoholic fatty liver disease and alcohol-associated liver disease.
- Citation: Gao FQ, Zhu JQ, Feng XD. Innovative mesenchymal stem cell treatments for fatty liver disease. World J Stem Cells 2024; 16(9): 846-853
- URL: https://www.wjgnet.com/1948-0210/full/v16/i9/846.htm
- DOI: https://dx.doi.org/10.4252/wjsc.v16.i9.846